In collaboration with Robert Wood Johnson University Hospital, an RWJBarnabas Health facility, the Blood and Marrow Transplant and Cellular Therapies Program at Rutgers Cancer Institute of New Jersey has been performing autologous and allogeneic stem cell transplants since 1995. Ours is the only such program in New Jersey offered at an NCI-designated Comprehensive Cancer Center.
The Blood and Marrow Transplant (BMT) Program treats patients with a number of illnesses including acute and chronic leukemias, myelodysplasia, lymphomas, Hodgkin disease, multiple myeloma, amyloidosis, and others.
The clinical and research interests of our clinicians focus on novel strategies to prevent graft-versus-host disease, improved umbilical cord blood transplants, and the development of cellular therapies that are less toxic than standard transplants such as CAR T-Cell therapy.
The Blood and Marrow Transplant and Cellular Therapies Program is accredited by the National Marrow Donor Program and the Foundation for the Accreditation of Cellular Therapy (FACT), and the program has been rated “Excellent” by the American College of Surgeons. We offer a full suite of oncology support services through which Oncology Nurse Navigators and transplant coordinators guide patients through treatment and beyond. Rutgers Cancer Institute also offers stem cell transplantation for children, adolescents and young adults with cancers and blood disorders through our Pediatric Stem Cell Transplantation and Cellular Therapies Program.
To request an appointment, call 844-CANCERNJ | Find Cellular Therapy Clinical Trials.
Your Blood and Marrow Transplant and Cellular Therapies Team
East Tower
The Blood and Marrow Transplant and Cellular Therapies Program location:
Learn more about the East Tower Location
Related News
Hematology/Oncology Data Showcase: 65th American Society of Hematology Annual Meeting and Exposition
Rutgers Cancer Institute of New Jersey and RWJBarnabas Health provide 36 oral and poster presentations that examine new advancements in the diagnosis, treatment, and management of blood cancers. Learn more.
Why is CAR T-Cell Therapy So Exciting? Answers From an Expert
CAR T-cell immunotherapy is a cutting-edge treatment option for patients with adult aggressive B-cell non-Hodgkin lymphoma or acute lymphoblastic leukemia in children or young adults. Learn More.
Leukemia and Transplant Team Collaboration
Neil Palmisiano, MD, MS discusses the collaboration process between teams when treating blood cancer patients using bone marrow transplants. Watch now.
Hematology/Oncology Research at Rutgers Cancer Institute
Andrew Evens, DO, MBA, MSc discusses research advances in blood cancers and cellular therapy happening at Rutgers Cancer Institute of New Jersey. Watch now.